Genetic variations in patients can render lung cancer medicines ineffective. Prof. Marc Diederich and his colleagues ascertained a biscoumarin-derivative to target patients that are resistant to other treatments.
Lung cancer is the most common cancer in the world and, with such a crucial role of this organ in the human body, it’s easy to understand the importance of finding an effective cure. Current research into finding new treatments aims at seeking molecules that can attack specific cancer cells. However, not every patient or cancer are the same due to genetic variation and this means that we are unlikely to find a one-size-fits-all medicine. A simple difference in the genetic code can make cancer cells resistant to treatments.